These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38491747)

  • 1. Alzheimer's disease and clinical trials.
    Paul D; Agrawal R; Singh S
    J Basic Clin Physiol Pharmacol; 2024 Jan; 35(1-2):31-44. PubMed ID: 38491747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Update on an Anti-Alzheimer Drug Candidate CT1812: A Sigma-2 Receptor Antagonist.
    Kaur G; Dar ZA; Bajpai A; Singh R; Bansal R
    Clin Ther; 2024 Sep; ():. PubMed ID: 39289058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's disease.
    van Dyck CH; Mecca AP; O'Dell RS; Bartlett HH; Diepenbrock NG; Huang Y; Hamby ME; Grundman M; Catalano SM; Caggiano AO; Carson RE
    Alzheimers Res Ther; 2024 Jan; 16(1):20. PubMed ID: 38273408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug candidates in clinical trials for Alzheimer's disease.
    Hung SY; Fu WM
    J Biomed Sci; 2017 Jul; 24(1):47. PubMed ID: 28720101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
    Izzo NJ; Yuede CM; LaBarbera KM; Limegrover CS; Rehak C; Yurko R; Waybright L; Look G; Rishton G; Safferstein H; Hamby ME; Williams C; Sadlek K; Edwards HM; Davis CS; Grundman M; Schneider LS; DeKosky ST; Chelsky D; Pike I; Henstridge C; Blennow K; Zetterberg H; LeVine H; Spires-Jones TL; Cirrito JR; Catalano SM
    Alzheimers Dement; 2021 Aug; 17(8):1365-1382. PubMed ID: 33559354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
    Chowdhury S; Chowdhury NS
    Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease.
    Neumann U; Ufer M; Jacobson LH; Rouzade-Dominguez ML; Huledal G; Kolly C; Lüönd RM; Machauer R; Veenstra SJ; Hurth K; Rueeger H; Tintelnot-Blomley M; Staufenbiel M; Shimshek DR; Perrot L; Frieauff W; Dubost V; Schiller H; Vogg B; Beltz K; Avrameas A; Kretz S; Pezous N; Rondeau JM; Beckmann N; Hartmann A; Vormfelde S; David OJ; Galli B; Ramos R; Graf A; Lopez Lopez C
    EMBO Mol Med; 2018 Nov; 10(11):. PubMed ID: 30224383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease.
    Moussa-Pacha NM; Abdin SM; Omar HA; Alniss H; Al-Tel TH
    Med Res Rev; 2020 Jan; 40(1):339-384. PubMed ID: 31347728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Allosteric Antagonist of the Sigma-2 Receptors-Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer's Disease: A Scoping Systematic Review.
    Rasheed A; Zaheer AB; Munawwar A; Sarfraz Z; Sarfraz A; Robles-Velasco K; Cherrez-Ojeda I
    Life (Basel); 2022 Dec; 13(1):. PubMed ID: 36675950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns.
    Lu D; Dou F; Gao J
    Drug Discov Ther; 2023; 17(6):440-444. PubMed ID: 38220210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing the success rate for Alzheimer's disease drug discovery and development.
    Becker RE; Greig NH
    Expert Opin Drug Discov; 2012 Apr; 7(4):367-70. PubMed ID: 22439785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.
    Ostrowitzki S; Bittner T; Sink KM; Mackey H; Rabe C; Honig LS; Cassetta E; Woodward M; Boada M; van Dyck CH; Grimmer T; Selkoe DJ; Schneider A; Blondeau K; Hu N; Quartino A; Clayton D; Dolton M; Dang Y; Ostaszewski B; Sanabria-Bohórquez SM; Rabbia M; Toth B; Eichenlaub U; Smith J; Honigberg LA; Doody RS
    JAMA Neurol; 2022 Nov; 79(11):1113-1121. PubMed ID: 36121669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks.
    Guthrie H; Honig LS; Lin H; Sink KM; Blondeau K; Quartino A; Dolton M; Carrasco-Triguero M; Lian Q; Bittner T; Clayton D; Smith J; Ostrowitzki S
    J Alzheimers Dis; 2020; 76(3):967-979. PubMed ID: 32568196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?
    Watt AD; Crespi GA; Down RA; Ascher DB; Gunn A; Perez KA; McLean CA; Villemagne VL; Parker MW; Barnham KJ; Miles LA
    Acta Neuropathol; 2014; 127(6):803-10. PubMed ID: 24803227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.
    Cummings JL; Cohen S; van Dyck CH; Brody M; Curtis C; Cho W; Ward M; Friesenhahn M; Rabe C; Brunstein F; Quartino A; Honigberg LA; Fuji RN; Clayton D; Mortensen D; Ho C; Paul R
    Neurology; 2018 May; 90(21):e1889-e1897. PubMed ID: 29695589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of PET Imaging to Assess the Efficacy of Thiethylperazine to Stimulate Cerebral MRP1 Transport Activity in Wild-Type and APP/PS1-21 Mice.
    Wölfl-Duchek M; Mairinger S; Hernández-Lozano I; Filip T; Zoufal V; Löbsch M; Stanek J; Kuntner C; Wanek T; Bauer M; Pahnke J; Langer O
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Neuroinflammation as a Therapeutic Strategy for Alzheimer's Disease: Mechanisms, Drug Candidates, and New Opportunities.
    Fu WY; Wang X; Ip NY
    ACS Chem Neurosci; 2019 Feb; 10(2):872-879. PubMed ID: 30221933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.